Effect of Nitric Oxide Donors on Uterine and Subendometrial Blood Flow in Patients With Unexplained Infertility

Not Applicable

Completed

• Conditions: Polycystic Ovary Syndrome; Infertility, Female
• Interventions: Device: Three dimensional power doppler; Drug: Nitroglycerin

• Registration Number: NCT03481582
• Lead Sponsor: Ain Shams University

Brief Summary

The purpose of the study to evaluate effect of nitroglycerin trans-dermal patches on uterine and sub-endometrial blood flow in women with unexplained infertility.

Detailed Description

90 female patients will be divided into 2 equal groups:

* Group I: 30 female patients with unexplained infertility.

* Group II: 30 female patients with unexplained infertility will receive nitroglycerin trans-dermal patch.

All subjects will be subjected to the following:

* Proper history taking on past medical history, menstrual history and infertility workup.

* Proper examination (general, abdominal and local examinations)

* Investigations to diagnose unexplained infertility ( male partner's semen analysis as well as documented ovulation and a patent uterine cavity and Fallopian tubes in the female partner).

* Group II (30 patients with unexplained infertility)will receive: (nitrodermal®) 5 mg (patch)as a source of Nitric oxide from 2nd day of cycle till maturation of the follicles ≥ 18 mm just for one cycle

* All women included in each group will be subjected to trans-vaginal ultrasound for folliculometry till maturation of the follicle ≥18mm.

* Once the follicle reached ≥18 mm 3D power Doppler will be used to assess the uterine and sub-endometrial blood flow.

* All women in each group will be subjected to urinary luteinizing hormone (LH) assay. The urinary LH assay will be started on cycle day 11, and repeated daily till detection of the LH surge.

* Six days after detection of the LH surge, 3D power Doppler will be repeated to assess the uterine and sub-endometrial blood flow.

Study Timeline

• Study Start: 2017-11-01
• Status Verified: 2018-03
• Primary Completion: 2018-03-01
• Study Completion: 2018-03-01
• Study First Submitted: 2018-03-19
• Study First Submitted QC: 2018-03-27
• Last Update Submitted: 2018-03-27
• Study First Posted: 2018-03-29
• Last Update Posted: 2018-03-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

1. Age between 20-35 years.6

2. Normal husband's semen analysis (WHO 2010 Criteria):

   • Count ≥15 million
   • Motility ≥ 32% progressive motility
   • Morphology ≥ 4% normal morphology

3. Documented ovulation ( basal body temperature , mid-luteal serum progesterone ≥3 ng / ml and ultrasound monitoring of ovulation).

4. Patent Fallopian tube and excluding uterine anomalies either by hystero-salpingogram (HSG) and/or laparoscopy.

5. Normal hormonal profile (serum progesterone, E2, F.S.H, LH and T.S.H In the 2ND Day of menstrual cycle)

Exclusion Criteria

1. Male factor of infertility.

2. Patients with uterine pathology as fibroids.

3. Tubal factor of infertility diagnosed by hysterosalpingography (HSG) or laparoscopy.

4. Patients with any contraindications for NO such as chronic liver and renal disease, known cardiac disease and migraine.

5. Diagnosis of PCO based on Rotterdam criteria, two out of three of the following are required to make the diagnosis (Rotterdam, 2004):

   • Oligo- and/or anovulation.
   • Clinical and/or biochemical signs of hyperandrogenism.
   • Polycystic ovaries (by transvaginal ultrasound): the morphology of PCO has been defined as an ovary with 12 or more follicles measuring 2-9 mm in diameter and/or increased ovarian volume (>10 cm3) (Balen et al, 2003).

6. Conditions that mimic PCOS; disorders that cause oligo/anovulation and/or hyperandrogenism, such as:

   • Thyroid disease.
   • Non classic congenital adrenal hyperplasia.
   • Hyperprolactinemia.
   • Androgen-secreting tumors.

7. Women who had any medical comorbidity (e.g. autoimmune disease or diabetes mellitus) and those who have been using medications to induce ovulation or medications known to affect the VEGF concentration (NSAIDs) were not included in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group without nitroglycerin	Three dimensional power doppler	They will be subjected to TV ultrasound for folliculometry till maturation of the follicle ≥18mm then Three dimensional power Doppler will be used to assess the uterine and sub-endometrial blood flow.
Group with nitroglycerin	Three dimensional power doppler	They will receive (nitrodermal®) 5 mg (patch) from 2nd day of cycle till maturation of the follicles ≥ 18 mm then Three dimensional power Doppler will be used to assess the uterine and sub-endometrial blood flow.
Group with nitroglycerin	Nitroglycerin	They will receive (nitrodermal®) 5 mg (patch) from 2nd day of cycle till maturation of the follicles ≥ 18 mm then Three dimensional power Doppler will be used to assess the uterine and sub-endometrial blood flow.

Primary Outcome Measures

Name	Time	Method
Three dimensional power Doppler	from day 10 of menstrual cycle until the follicle reached ≥18 mm	Once the follicle reached ≥18 mm 3D power Doppler will be used to assess the uterine and sub-endometrial blood flow

Secondary Outcome Measures

Name	Time	Method
Pregnancy rate	2 weeks after follicle reached ≥18 mm	serum B-HCG titre if the patient suffered from amenorrhea

Trial Locations

Locations (1)

Department of obstetrics and gynaecology, faculty of medicine, Ain shams university; 🇪🇬 Cairo, Egypt